Cogstate (CGS) H2 2024 earnings summary

Executive summary

• Group revenue increased 7% year-over-year to $43.4m, driven by 9% growth in Clinical Trials revenue, despite a 21% decline in new clinical trial sales contracts and a decrease in Healthcare revenue due to the Eisai agreement renegotiation.

• Profit before tax more than doubled to $7.1m, up 135%, reflecting strong operational leverage and cost management.

• The company executed $27m in clinical trial sales contracts, with $14m from non-Alzheimer's indications, representing 60% growth in that segment.

• The renegotiation of the Eisai license agreement returned IP control to the company, enabling new commercial opportunities and direct digital assessment offerings.

• The share buyback program was suspended after repurchasing 4.4m shares for AUD $6.4m to preserve capital for potential strategic acquisitions.

Financial highlights

• Clinical Trials revenue grew 9% to $39.4m, while Healthcare revenue declined 9% to $4.0m due to the Eisai contract amendment.

• Gross profit margin improved by 5 percentage points to 57%, with gross profit up 18% to $24.6m.

• Operating expenses declined 4% year-over-year to $15.3m, despite higher bonus accruals.

• Operating cash flow rose to $5.8m from $0.7m, with net cash at $29.4m at year-end.

• EBIT reached $6.5m, up 196% from the prior year.

Outlook and guidance

• Management expects revenue and profit growth in FY2025, supported by a strong start with $9.3m in new clinical trial contracts and $29.6m in gross contracts signed by August 21, 2024.

• No specific financial guidance provided; future revenue recognition depends on further contract execution.

• The company targets EBIT margins in the 20%+ range, with technology investments expected to support further margin expansion.

• Ongoing opportunities in Alzheimer's disease and other indications such as mood and sleep disorders.